title: Role of IN-1233 in the prevention of neointimal hyperplasia after stent placement in a rat artery model.
abstract: OBJECTIVE
  To evaluate the efficacy of an activin receptor-like kinase (ALK) 5 inhibitor, IN-1233, for the prevention of neointimal hyperplasia after bare stent placement in a rat common iliac artery (CIA) model.
  
  
  METHODS
  All experiments were approved by the committee of animal research. A self-expanding metallic bare stent (2 mm × 6 mm) was inserted into the left CIA of 26 Sprague-Dawley male rats (300-360 g) under fluoroscopic guidance. IN-1233 was injected via the intraperitoneal route daily in 13 rats for 8 weeks after stent placement (group A); the other 13 rats underwent stent placement only (group B). Angiography was performed immediately and 4 weeks and 8 weeks after stent placement. Rats were sacrificed at 8 weeks after stent placement, and histologic findings were obtained. The neointimal area (NA), percentage of neointimal hyperplasia (%NH), and neointimal-to-medial area ratio (N/M) were assessed and compared between the two groups.
  
  
  RESULTS
  Stent placement was technically successful. In 25 rats, arteries with stent placement were angiographically patent, whereas 1 rat in group B had an occlusion. The NA (0.31 mm(2) ± 0.09 vs 0.56 mm(2) ± 0.17; P < .001), the %NH (26.16% ± 8.75 vs 44.71% ± 17.75; P < .001) and the N/M (1.93 ± 0.77 vs 4.77 ± 2.26; P < .001) were significantly decreased in group A compared with group B.
  
  
  CONCLUSIONS
  IN-1233 was shown in this study to be effective for the prevention of neointimal hyperplasia after bare metallic stent placement in a rat CIA model.
authors.affiliation: Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Poongnap-2dong, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Hyun-Jung
authors.initials: HJ
authors.lastname: Yoon
authors.forename: Ho-Young
authors.initials: HY
authors.lastname: Song
authors.forename: Jin Hyoung
authors.initials: JH
authors.lastname: Kim
authors.forename: Kang-Sun
authors.initials: KS
authors.lastname: Hong
authors.forename: Yeon Joo
authors.initials: YJ
authors.lastname: Kim
authors.forename: Hyung Gyu
authors.initials: HG
authors.lastname: Park
authors.forename: Dae-Kee
authors.initials: DK
authors.lastname: Kim
mesh_terms: D000818:Animals; D001549:Benzamides / Q000008:administration & dosage / Q000494:pharmacology*; D057510:Endovascular Procedures / Q000009:adverse effects / Q000295:instrumentation*; D006965:Hyperplasia; D007083:Iliac Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D007274:Injections, Intraperitoneal; D008297:Male; D008670:Metals; D011474:Prosthesis Design; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology*; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000378:metabolism; D015607:Stents; D013997:Time Factors; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology
chemical_list: C538835:3-((4-(6-methylpyridin-2-yl)-5-(quinolin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; D001549:Benzamides; D008670:Metals; D047428:Protein Kinase Inhibitors; D011804:Quinolines; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077293:Receptor, Transforming Growth Factor-beta Type I; C000625843:Tgfbr1 protein, rat